Regulus Therapeutics Inc (RGLS)
2.27
+0.05
(+2.25%)
USD |
NASDAQ |
Apr 25, 16:00
2.29
+0.02
(+0.88%)
Pre-Market: 20:00
Regulus Therapeutics Cash from Financing (TTM): 11.82M for Dec. 31, 2023
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 11.82M |
September 30, 2023 | 12.69M |
June 30, 2023 | 16.89M |
March 31, 2023 | 3.684M |
December 31, 2022 | 4.491M |
September 30, 2022 | 36.90M |
June 30, 2022 | 32.40M |
March 31, 2022 | 47.40M |
December 31, 2021 | 53.74M |
September 30, 2021 | 31.38M |
June 30, 2021 | 30.32M |
March 31, 2021 | 15.92M |
December 31, 2020 | 9.513M |
September 30, 2020 | 23.97M |
June 30, 2020 | 24.97M |
March 31, 2020 | 39.21M |
December 31, 2019 | 39.93M |
September 30, 2019 | 12.85M |
June 30, 2019 | 12.03M |
March 31, 2019 | -2.874M |
December 31, 2018 | -2.83M |
September 30, 2018 | -0.258M |
June 30, 2018 | 43.77M |
Date | Value |
---|---|
March 31, 2018 | 43.85M |
December 31, 2017 | 43.42M |
September 30, 2017 | 43.37M |
June 30, 2017 | 0.456M |
March 31, 2017 | 20.29M |
December 31, 2016 | 20.55M |
September 30, 2016 | 22.23M |
June 30, 2016 | 25.54M |
March 31, 2016 | 6.63M |
December 31, 2015 | 7.017M |
September 30, 2015 | 83.24M |
June 30, 2015 | 79.86M |
March 31, 2015 | 78.97M |
December 31, 2014 | 88.24M |
September 30, 2014 | 10.37M |
June 30, 2014 | 56.46M |
March 31, 2014 | 56.48M |
December 31, 2013 | 46.47M |
September 30, 2013 | 113.49M |
June 30, 2013 | 71.01M |
March 31, 2013 | 70.73M |
December 31, 2012 | 70.48M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
3.684M
Minimum
Mar 2023
53.74M
Maximum
Dec 2021
24.22M
Average
23.97M
Median
Sep 2020
Cash from Financing (TTM) Benchmarks
ACADIA Pharmaceuticals Inc | 25.13M |
ADMA Biologics Inc | -38.99M |
FibroGen Inc | 122.75M |
Protara Therapeutics Inc | -0.091M |
Amylyx Pharmaceuticals Inc | 3.543M |